New Delhi: AstraZeneca has sent a legal notice to the Serum Institute of India (SII) over the delay in the supply of the coronavirus vaccine. The SII, therefore, has sought assistance from the Government of India in the form of grants to double the production of Covishield. The serum is made and sold from the covishield brand name in India to the corona vaccine made by Oxford-AstraZeneca.
SII CEO Adar Poonawalla on Tuesday said about Rs 3,000 crore would be required to increase the production capacity of the corona vaccine. Poonawalla told the media, "We need roughly Rs 3,000 crore, which is not a small figure because we have already spent thousands of crores of rupees. We have to find other new ways to build our capacity. He said the company expects the production capacity of the Covishield vaccine to increase to 11 crores every month from June.
Poonawalla said the company is producing 20 lakh doses daily. "We have given more than 100 million doses in India alone and exported 60 million doses to other countries," he said. Serum Institute (SII) as well as other vaccine growers have also agreed with the government not to take advantage.